EE05357B1 - Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine - Google Patents

Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine

Info

Publication number
EE05357B1
EE05357B1 EEP200400005A EEP200400005A EE05357B1 EE 05357 B1 EE05357 B1 EE 05357B1 EE P200400005 A EEP200400005 A EE P200400005A EE P200400005 A EEP200400005 A EE P200400005A EE 05357 B1 EE05357 B1 EE 05357B1
Authority
EE
Estonia
Prior art keywords
distinct segments
tablet containing
tablet
distinct
segments
Prior art date
Application number
EEP200400005A
Other languages
English (en)
Estonian (et)
Inventor
Fanara Domenico
Guichaux Anthony
Berwaer Monique
Deleers Michel
Original Assignee
Ucb, Farchim, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb, Farchim, S.A. filed Critical Ucb, Farchim, S.A.
Publication of EE200400005A publication Critical patent/EE200400005A/xx
Publication of EE05357B1 publication Critical patent/EE05357B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200400005A 2001-06-28 2002-06-10 Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine EE05357B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30125001P 2001-06-28 2001-06-28
EP01115807 2001-06-28
PCT/EP2002/006342 WO2003002098A1 (en) 2001-06-28 2002-06-10 Tablet comprising cetirizine and pseudoephedrine

Publications (2)

Publication Number Publication Date
EE200400005A EE200400005A (et) 2004-02-16
EE05357B1 true EE05357B1 (et) 2010-12-15

Family

ID=56290291

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400005A EE05357B1 (et) 2001-06-28 2002-06-10 Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine

Country Status (22)

Country Link
EP (1) EP1404304B1 (de)
JP (1) JP4041460B2 (de)
KR (1) KR100926410B1 (de)
CN (1) CN100490809C (de)
AT (1) ATE432068T1 (de)
AU (1) AU2002345024B2 (de)
BR (1) BR0210650A (de)
CA (1) CA2451519C (de)
CZ (1) CZ20033454A3 (de)
DK (1) DK1404304T3 (de)
EE (1) EE05357B1 (de)
ES (1) ES2324769T3 (de)
HU (1) HU229803B1 (de)
MX (1) MXPA03010430A (de)
NZ (1) NZ530289A (de)
PL (1) PL206069B1 (de)
PT (1) PT1404304E (de)
RO (1) RO122476B1 (de)
RU (1) RU2286784C2 (de)
SI (1) SI1404304T1 (de)
SK (1) SK287645B6 (de)
WO (1) WO2003002098A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159287A0 (en) * 2001-06-28 2004-06-01 Ucb Farchim Sa Tablet comprising cetirizine and pseudoephedrine
KR100698400B1 (ko) 2004-04-14 2007-03-23 이은주 탈모증 및 전립선비대증 치료를 위한 약제학적 조성물
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
CA2674084C (en) * 2006-12-26 2013-05-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
EP2521584B1 (de) 2010-01-05 2018-10-17 MicroDose Therapeutx, Inc. Inhalationsvorrichtung
KR101193495B1 (ko) 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
US9044479B2 (en) * 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
CN102302497A (zh) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 一种治疗过敏性鼻炎的制剂及其制备方法
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
KR101372324B1 (ko) * 2012-02-09 2014-03-13 동국대학교 경주캠퍼스 산학협력단 알러지성 비염 치료를 위한 한방 치료제 및 슈도에페드린을 함유한 복합서방형의 약제학적 조성물
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2016140630A1 (en) 2015-03-05 2016-09-09 PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş. An effervescent composition comprising levocetirizine and pseudoephedrine
AU2021217209A1 (en) * 2020-02-03 2022-09-29 Kenvue Brands Llc A single layer chewable tablet comprising cetirizine
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
EP0811374A1 (de) * 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine

Also Published As

Publication number Publication date
SK287645B6 (sk) 2011-05-06
JP4041460B2 (ja) 2008-01-30
WO2003002098A1 (en) 2003-01-09
ES2324769T3 (es) 2009-08-14
MXPA03010430A (es) 2004-12-06
ATE432068T1 (de) 2009-06-15
DK1404304T3 (da) 2009-07-13
NZ530289A (en) 2004-11-26
KR100926410B1 (ko) 2009-11-12
EP1404304A1 (de) 2004-04-07
EE200400005A (et) 2004-02-16
CZ20033454A3 (cs) 2004-08-18
PT1404304E (pt) 2009-06-26
HUP0400386A3 (en) 2006-02-28
RU2286784C2 (ru) 2006-11-10
CN100490809C (zh) 2009-05-27
EP1404304B1 (de) 2009-05-27
AU2002345024B2 (en) 2006-09-07
PL206069B1 (pl) 2010-06-30
BR0210650A (pt) 2004-10-05
HUP0400386A2 (hu) 2004-08-30
CN1520285A (zh) 2004-08-11
SI1404304T1 (sl) 2009-10-31
JP2004536829A (ja) 2004-12-09
HU229803B1 (en) 2014-07-28
CA2451519C (en) 2007-11-06
CA2451519A1 (en) 2003-01-09
RO122476B1 (ro) 2009-07-30
SK15502003A3 (sk) 2004-05-04
KR20040007756A (ko) 2004-01-24
RU2004101231A (ru) 2005-04-20
PL366800A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
NO20034056D0 (no) Proliferative sykdommer
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
TW200505875A (en) Novel compounds
GB0111186D0 (en) Novel compounds
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
TW200509896A (en) Analeptic and drug combinations
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
WO2004094465A8 (en) Synthetic molecules that mimic chemokines
SE0000303D0 (sv) Novel compounds
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE60322577D1 (de) Tablette enthaltend efletirizin und pseudoephedrin
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
WO2006044548A3 (en) Clopidogrel compositions
EA200500538A1 (ru) Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений нервной системы
ATE390144T1 (de) Behandlung von fibrosen
HN2002000106A (es) Piper nigrum como agente antiinflamatorio en compuestos orales y dermatologicos. (pimienta negra).

Legal Events

Date Code Title Description
HB1A Correction of owner name or address
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name